MedTrace Logo

A Study to Explore the Effect of Acid-reducing Agents

NCT04935112 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2022-08-26

No results posted yet for this study

Summary

A Phase 1 Study of the Effect of Acid-reducing Agents on the Pharmacokinetics of a Single Oral Dose of Sitravatinib in Healthy Adult Subjects. The study is a single-center, open-label, 2-period, 2-treatment, fixed-sequence crossover, parallel-group study.

Conditions

  • Healthy Adults

Interventions

DRUG

Sitravatinib

100 mg sitravatinib on Day 1

DRUG

Pantoprazole

40 mg QD on Day 1 to Day 7 of Period 2 in Group 1

DRUG

Famotidine

40 mg PO 2 hrs after sitravatinib in Period 2 of Group 2

Sponsors & Collaborators

  • Mirati Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Curtis Chin, MD · Mirati Therapeutics Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-07
Primary Completion
2021-08-12
Completion
2022-07-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04935112 on ClinicalTrials.gov